Skip to main content

Advertisement

Log in

Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The treatment of diffuse large B-cell lymphoma with chemotherapy was retrospectively evaluated in 348 patients who had received at least three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like, ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)-like or CHVmP-BV (cyclophosphamide, hydroxorubicin, Vm-26, prednisone, vincristine and bleomycin) treatment in Belgium between 1995 and 2000. In our sample, the proportion who received each of the three regimens was 78.4, 16.4, and 5.2%, respectively. Of those prescribed CHOP-like regimens, 15% received <80% average relative dose intensity (ARDI). In 210 patients treated with CHOP-21 (77% of the CHOP-like group), median survival was 7.08 years in those who received >90% of the ARDI, significantly longer than in those who received ≤;90% of the ARDI (p = 0.002). Dose reductions and/or delays, mainly due to hematological toxicities, resulted in a reduction in treatment intensity. These data indicate that patient outcome is improved when the intensity of chemotherapy treatment is optimal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Armitage JO, Weisenburger DD (1998) New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 16:2780–2795

    PubMed  CAS  Google Scholar 

  2. Bastion Y, Bosly A, Gisselbrecht C, Reyes F, Tilly H, Herbrecht R et al (1993) A randomized double-blind phase III study of filgrastim (recombinant human G-CSF) vs placebo during intensive induction chemotherapy in 55 to 69-year old patients with poor prognosis aggressive non-Hodgkin’s lymphoma. Blood 82:143a (abstract)

    Google Scholar 

  3. Bjorkholm M, Osby E, Hagberg H, Kvaloy S, Teerenhovi L, Myhre J et al (1999) Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin’s lymphoma (ASH 1999). 94:abstract 2665

  4. Bobey N, Woodman RC (1998) Neutropenic complications in advanced-stage non-Hodgkin’s lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF). Clin Invest Med 21:63–70

    PubMed  CAS  Google Scholar 

  5. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340

    PubMed  CAS  Google Scholar 

  6. Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh JW, Jack A et al (1999) The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 35:627–633

    Article  PubMed  CAS  Google Scholar 

  7. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N (1989) LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018–1026

    PubMed  CAS  Google Scholar 

  8. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 364:235–242

    Article  Google Scholar 

  9. Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller TP, Grozea PN et al (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 4:295–305

    PubMed  CAS  Google Scholar 

  10. Doorduijn JK, van der Holt B, van der Hem KG, van Imhoff GW, Kramer MHH, van Oers MHJ et al (2000) Randomized trial of granulocyte-colony stimulating factor (G-CSF) added to CHOP in elderly patients with aggressive non-Hodgkin’s lymphoma (NHL). Blood 96:133a (abstract 575)

    Google Scholar 

  11. Epelbaum R, Faraggi D, Ben-Arie Y, Ben-Shahar M, Haim N, Ron Y et al (1990) Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 66:1124–1129

    Article  PubMed  CAS  Google Scholar 

  12. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006

    Article  PubMed  CAS  Google Scholar 

  13. Greil R (1998) Prognosis and management strategies of lymphatic neoplasias in the elderly. I. Aggressive non-Hodgkin’s lymphomas. Oncology 55:189–217

    Article  PubMed  CAS  Google Scholar 

  14. Jaffe ES, Harris NL, Stein H, Verdiman JW (2001) WHO classifications of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon

    Google Scholar 

  15. Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8:963–977

    PubMed  CAS  Google Scholar 

  16. Lepage E, Gisselbrecht C, Haioun C, Sebban C, Tilly H, Bosly A et al (1993) Prognostic significance of received relative dose intensity in non-Hodgkin’s lymphoma patients: application to LNH-87 protocol. The GELA (Groupe d’Etude des Lymphomes de l’Adulte). Ann Oncol 4:651–656

    PubMed  CAS  Google Scholar 

  17. Meerwaldt JH, Carde P, Somers R, Thomas J, Kluin-Nelemans JC, Bron D et al (1997) Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III–IV intermediate- and high-grade non-Hodgkin’s lymphoma. The EORTC Lymphoma Cooperative Group. Ann Oncol 8:67–70

    Article  PubMed  Google Scholar 

  18. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grognan TM et al (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 339:21–26

    Article  PubMed  CAS  Google Scholar 

  19. Ries LAG, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (eds). SEER Cancer Statistics Review, 1973–1996, National Cancer Institute. Bethesda, MD, 1999

  20. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM et al (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 80:1430–1436

    PubMed  CAS  Google Scholar 

  21. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AZC, Rübe C et al (2004) 2-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634–641

    Article  PubMed  CAS  Google Scholar 

  22. Picozzi VJ, Pohlman BL, Morrison VA, Lawless GD, Lee MW, Kerr RO et al. (2001) Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin’s lymphoma. Oncology (Williston Park) 15:1296–1306

    CAS  Google Scholar 

  23. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A et al (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin’s lymphoma. Blood 102:4284–4289

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was supported by Amgen Belgium.

Conflict of interest statement

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to A. Bosly.

Additional information

See Appendix for a list of participating centers and physicians.

Appendix

Appendix

Names of participating centers and physicians

Dr. R. De Bock (Centrumziekenhuis, campus Middelheim, Antwerpen); Dr. P. Zachée (Centrumziekenhuis campus Stuivenberg, Antwerpen); Prof. G. Verhoef (U.Z. Gasthuisberg, Leuven); Prof. Z. Berneman (U.Z. Antwerpen); Dr. Ph. Spaas (St. Norbertusziekenhuis, Duffel); Dr. D. De Bal (St. Maartenziekenhuis, Duffel); Dr. J. Meyskens (St. Elisabethziekenhuis, Turnhout); Dr. P. Specenier (AZ Jan Portaels, Vilvoorde); Dr. D. Vanstraelen (Virga Jesseziekenhuis, Hasselt); Dr. A. Van Hoof (AZ St. Jan, Brugge); Dr. M. Petrick (St. Lucasziekenhuis, Gent); Dr. K. Van Eygen (AZ Groeningen, Kortrijk); Prof. H. Demuynck (H. Hartziekenhuis, Roeselare); Dr. F. Trullemans (U.Z. V.U. Brussel); Prof. F. Offner (U.Z. Gent); Prof. A. Ferrant (U.C.L. St Luc, Bruxelles); Dr. D. Boulet (Clinique St. Joseph, Mons); Dr. M. André (C.H. Notre-Dame Reine Fabiola, Charleroi); Dr. Ph. Mineur (Clinique St. Joseph, Gilly); Prof. D. Bron (Institut J. Bordet, Bruxelles); Prof. W. Feremans (Hôpital Erasme, U.L. Bruxelles); Dr. M. Maerevoet (Clinique St. Pierre, Ottignies); Dr. S. Lampertz (Hôpital Bois de l’Abbaye, Seraing); Dr. P. Pierre (Clinique St. Joseph, Arlon); Dr. L. Montfort (Clinique St. Luc, Bouge); Prof. A. Bosly (U.C.L. Mont Godinne, Yvoir and Clinique Sainte-Elisabeth, Namur); Prof. G. Fillet (C.H.U. Sart Tilman, Liège); Dr. L. Longrée (Hôpital St Joseph, Liège); Dr. M. Reginster (C.H. Hutois, Huy), Dr. J. Collignon (C.H. Hutois, Huy).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bosly, A., Bron, D., Van Hoof, A. et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87, 277–283 (2008). https://doi.org/10.1007/s00277-007-0399-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-007-0399-y

Keywords

Navigation